Anti-EMR1 antibodies

US9045539B2 · kind B2 · utility

Assignee

• KaloBios Pharmaceuticals, Inc. · US

Inventors

• Kenneth Luehrsen · Rue de l'Église, US
• Mark Baer · South San Francisco, US
• Christopher R. Bebbington · San Mateo, US
• David Martinez · Sunnyvale, US
• Varghese Palath · South San Francisco, US
• Swathi Sujatha-Bhaskar · South San Francisco, US
• Nenad TOMASEVIC · South San Francisco, US
• Jason WILLIAMS · Edgewater, US
• Geoffrey T. Yarranton · Burlingame, US

Key dates

• Filing date: May 25, 2012
• Grant date: Jun 2, 2015
• Expiry date: May 25, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/732
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.